Literature DB >> 16887379

Nutritional supplement chromium picolinate generates chromosomal aberrations and impedes progeny development in Drosophila melanogaster.

Dontarie M Stallings1, Dion D D Hepburn, Meredith Hannah, John B Vincent, Janis O'Donnell.   

Abstract

Chromium picolinate, [Cr(pic)(3)], is a popular nutritional supplement found in a variety of consumer products. Despite its popularity, safety concerns over its use have arisen. The supplement has been shown to generate clastogenic damage, mitochondrial damage, oxidative damage, and mutagenic effects in cultured cells and oxidative DNA damage and lipid peroxidation in rats. Recently [Cr(pic)(3)] has been demonstrated to generate heritable genetic change and delays in progeny development in Drosophila melanogaster. Based on the damage to chromosomes of cultured cells and of animal models, similar chromosome damage appeared to be a likely source of the mutagenic effects of the supplement in Drosophila. The current three-part study examines the effects of several chromium-containing supplements and their components on hatching and eclosion rates and success of development of first generation progeny of adult Drosophila fed food containing these compounds. It further examines the effects of the compounds on longevity of virgin male and female adults. Finally, the chromosomes in the salivary glands of Drosophila late in the third instar larval stage, which were the progeny of Drosophila whose diets were supplemented with nutritional levels of [Cr(pic)(3)], are shown to contain on average over one chromosomal aberration per two identifiable chromosomal arms. No aberrations were observed in chromosomes of progeny of untreated flies. The results suggest that human consumption of the supplement should be a matter of concern and continued investigation to provide insight into the requirements of chromium-containing supplements to give rise to genotoxic effects.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16887379     DOI: 10.1016/j.mrgentox.2006.06.019

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  6 in total

1.  Renal and glycemic effects of high-dose chromium picolinate in db/db mice: assessment of DNA damage.

Authors:  Mahmood S Mozaffari; Babak Baban; Rafik Abdelsayed; Jun Yao Liu; Hereward Wimborne; Nancy Rodriguez; Worku Abebe
Journal:  J Nutr Biochem       Date:  2011-09-29       Impact factor: 6.048

2.  Competition for amino acids between Wolbachia and the mosquito host, Aedes aegypti.

Authors:  Eric P Caragata; Edwige Rancès; Scott L O'Neill; Elizabeth A McGraw
Journal:  Microb Ecol       Date:  2013-12-13       Impact factor: 4.552

3.  Chromium-picolinate therapy in diabetes care: individual outcomes require new guidelines and navigation by predictive diagnostics.

Authors:  Kristina Yeghiazaryan; Hans H Schild; Olga Golubnitschaja
Journal:  Infect Disord Drug Targets       Date:  2012-10

4.  Chromium-picolinate therapy in diabetes care: molecular and subcellular profiling revealed a necessity for individual outcome prediction, personalised treatment algorithms and new guidelines.

Authors:  Kristina Yeghiazaryan; Viktoriya Peeva; Aparna Shenoy; Hans H Schild; Olga Golubnitschaja
Journal:  Infect Disord Drug Targets       Date:  2011-04

5.  Trace elements in glucometabolic disorders: an update.

Authors:  Nicolas Wiernsperger; Jeanrobert Rapin
Journal:  Diabetol Metab Syndr       Date:  2010-12-19       Impact factor: 3.320

6.  Opinion controversy to chromium picolinate therapy's safety and efficacy: ignoring 'anecdotes' of case reports or recognising individual risks and new guidelines urgency to introduce innovation by predictive diagnostics?

Authors:  Olga Golubnitschaja; Kristina Yeghiazaryan
Journal:  EPMA J       Date:  2012-10-07       Impact factor: 6.543

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.